J. Joseph Kim plaintiffs

Inovio Pharmaceuticals is a clinical-stage biotechnology company focused on the development of DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases. The company's proprietary platform, ASPIRE, utilizes DNA plasmids delivered via the Cellectra electroporation device to induce a functional immune response. Inovio's lead candidate, INO-3107, is in late-stage development for Recurrent Respiratory Papillomatosis (RRP), while VGX-3100 is being evaluated for HPV-related cervical pre-cancer. The company gained significant public attention and faced subsequent legal challenges, including a securities class action involving former CEO J. Joseph Kim, regarding its COVID-19 vaccine development claims.